BPI Labs

What BPI Labs does

BPI Labs, LLC is a US sterile injectable pharmaceutical manufacturer headquartered in Largo, Florida, operating as a wholly-owned subsidiary of Belcher Pharmaceuticals since its 2012 founding. The company produces an FDA-approved portfolio spanning generic injectables (Carboplatin, Methylene Blue 1%, Epinephrine, and Dehydrated Alcohol) and one specialty product (ABLYSINOL for hypertrophic obstructive cardiomyopathy), distributed directly to US hospitals, clinics, and pharmacies as a 503B Outsourcing Facility under cGMP compliance with 21 CFR Parts 210 and 211.

The company's core manufacturing platform consists of fully humanless robotic fill-finish suites operating inside 100% isolated ISO-grade A enclosures, supported by automated visual inspection, one-time-use disposable pathways, and in-house analytical, microbiological, R&D, and validation (IQ/OQ/PQ) capabilities. Batch capacity scales from 1 to 1,000 liters (expandable to 2,000 liters), with continuous 24/7 production of small-volume parenterals and pre-filled syringes. The R&D pipeline is explicitly oriented toward complex and high-value difficult-to-develop sterile formulations across multiple therapeutic areas.

Commercially, BPI Labs operates a B2B enterprise sales model with direct relationships to healthcare providers, multi-year contract pricing on a unit basis, and a recently launched Product Partnering service for co-development and contract manufacturing. All sales are quote-based and not publicly disclosed; the company does not currently disclose revenue, headcount detail beyond a 51-100 range, or independent ownership structure beyond its Belcher Pharmaceuticals parent.

Name

BPI Labs

Legal name

BPI Labs, LLC

Website

https://bpi-labs.com

Company type

Private

Founded year

2012

Operating status

Operating

Headcount range

51–100 employees

Short description

BPI Labs is a Largo, Florida-based sterile injectable pharmaceutical manufacturer and Belcher Pharmaceuticals subsidiary, producing FDA-approved generic and specialty injectables for US hospitals, clinics, and pharmacies via automated robotic fill-finish technology.

Ownership category

akta.pro rank

Product category

Sterile Injectable Pharmaceuticals

NAICS

Pharmaceutical Preparation Manufacturing (325412), Pharmaceutical and Medicine Manufacturing (3254)

SIC

Pharmaceutical Preparations (2834)

akta.pro primary industry

Contract Development & Manufacturing for Generics (CDMO/CMO) (HLAIABAI)

akta.pro secondary industries

Fill-Finish & Aseptic Drug Product Manufacturing (Biologics/ATMP) (HLAGAGAG), GMP Quality, Validation & Regulatory Support (GMP/CSV/Qualification) (HLAGAGAL), Process Development & Tech Transfer Services (upstream/downstream) (HLAAAKAF), GMP Scale-Up, Tech Transfer & Process Validation (PPQ) (HLAGAHAL)

Keywords

• Sterile injectable manufacturing
• Generic injectable pharmaceuticals
• 503B outsourcing facility
• CGMP pharmaceutical production
• Sterile fill-finish services

Headquarters

HQ city

Largo

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Operations, Supply Chain, Technology or R&D, Infrastructure, Marketing or Sales

Revenue model

1. Generic Sterile Injectable Pharmaceuticals: Manufacturing and sale of FDA-approved generic sterile injectable pharmaceuticals including Carboplatin Injection, Methylene Blue 1% Injection, Epinephrine Injection, and Dehydrated Alcohol. Products sold in various forms including vials, ampoules, and pre-filled syringes to healthcare providers.
2. Specialty Pharmaceutical Products: Specialty branded products such as ABLYSINOL for treatment of hypertrophic obstructive cardiomyopathy, representing higher-value therapeutic treatments.

Pricing tiers

Go-to-market motion1 record

Distribution channels3 records

Marketing channels2 records

Core offering

BPI Labs is an FDA-registered, 503B outsourcing facility that manufactures and sells FDA-approved generic and specialty sterile injectable pharmaceuticals—including Carboplatin, Methylene Blue 1%, Epinephrine, Dehydrated Alcohol, and the specialty product ABLYSINOL®—to hospitals, clinics, and pharmacies across the United States. Production occurs 24/7 in fully isolated, humanless robotic fill-finish suites under cGMP compliance, with scalable 1–1000L (up to 2000L) batch capacity and in-house R&D, analytical, microbiological, and validation capabilities.

Product overview

BPI Labs operates as a pharmaceutical manufacturer offering a portfolio of FDA-approved generic sterile injectable medications and specialty products, supported by advanced manufacturing services. The portfolio includes ABLYSINOL® (a specialty product for cardiac conditions), DEHYDRATED ALCOHOL, CARBOplatin Injection, Methylene Blue 1% Injection, and Epinephrine Injection in various formulations. These generic products are complemented by the company's core manufacturing capabilities featuring fully robotic, humanless sterile fill-finish production in ISO-grade environments, with 24/7 production capacity for small-volume parenterals and pre-filled syringes. The company also offers product partnering services for pharmaceutical partners seeking manufacturing expertise.

Differentiator

Problem solved

Functional benefit

Products and services

• ABLYSINOL® Specialty injectable indicated to induce controlled cardiac septal infarction to improve exercise capacity in adults with symptomatic hypertrophic obstructive cardiomyopathy who are not candidates for surgical myectomy; sold to healthcare providers.
• DEHYDRATED ALCOHOL Injection FDA-approved generic injectable medication available in vial and ampoule forms for clinical use.
• CARBOplatin Injection Generic injectable chemotherapy agent available in three dosage strengths: 600 mg/60 mL, 450 mg/45 mL, and 150 mg/15 mL, supplied as vials.
• Methylene Blue 1% Injection Generic injectable medication available in 10 mg/mL concentration in prefilled syringe format (5 count) and vials (10 count).
• Epinephrine Injection, USP (Multidose Vial) Generic emergency medication available in multidose vials: 30 mg/30 mL (1 mg/mL) and 10 mg/10 mL (1 mg/mL) concentrations.
• Epinephrine Injection, USP (Ampoule) Generic emergency medication in 1 mg/mL concentration, supplied in ampoules of 10 count.
• Sterile Injectable Manufacturing Services Advanced sterile manufacturing services using fully isolated, robotic fill-finish technology including small-volume parenteral solutions (SVPs) and pre-filled syringes, operating 24/7 with in-house analytical and microbiological labs.
• Product Partnering Strategic partnership services for co-development and manufacturing of sterile injectable pharmaceuticals with pharmaceutical companies seeking manufacturing capabilities.

Segments3 records

Ideal customer profiles4 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature6 records

Scale indicators6 records

Recent moves6 records

Expansion highlights5 records

Direct peers

• Hikma Pharmaceuticals: Hikma's Injectables division manufactures generic sterile injectable pharmaceuticals across hospital therapeutic areas, competing directly with BPI Labs in the U.S. generic injectable market for oncology, anesthesia, and emergency care products.
• Amphastar Pharmaceuticals: Amphastar is a U.S.-focused specialty injectable manufacturer producing generic and branded injectables including emergency care and hospital products, directly comparable to BPI's carboplatin, epinephrine, and methylene blue portfolio.
• Sagent Pharmaceuticals: Sagent focuses on generic injectable pharmaceuticals for the U.S. hospital market with a portfolio of oncology, anti-infective, and critical care injectables, making it a direct competitor in BPI's core therapeutic categories.
• Leiters Health: Leiters is an FDA-registered 503B outsourcing facility producing sterile compounded and manufactured injectable preparations for hospitals and health systems, sharing BPI's regulatory model and customer base.
• SCA Pharma: SCA Pharma operates as an FDA-registered 503B outsourcing facility producing sterile injectable preparations for hospitals nationwide, operating a business model and regulatory posture nearly identical to BPI Labs.
• Nephron Pharmaceuticals: Nephron operates one of the largest FDA-registered 503B outsourcing facilities in the U.S., producing generic sterile injectables including respiratory and emergency medications, making it a direct competitor in hospital injectable supply.

Broad incumbents

• Aurobindo Pharma (USA): Aurobindo is a large global generic pharmaceutical manufacturer with a major U.S. injectables franchise, competing with BPI in oncology and hospital generic injectables from a much broader portfolio base.
• Fagron: Fagron is a global leader in pharmaceutical compounding including 503B outsourcing facility operations in the U.S., providing a broader portfolio of sterile and non-sterile preparations that overlaps with BPI's contract manufacturing model.
• Apotex (U.S.): Apotex is a major global generic pharmaceutical manufacturer with a U.S. injectables presence, competing with BPI in commoditized sterile injectable categories across hospital systems and group purchasing organizations.
• Pfizer CentreOne: Pfizer's contract manufacturing arm offers sterile injectable fill-finish and contract development services from a global network of facilities, overlapping with BPI's product partnering and CDMO capabilities but at vastly larger scale.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

• Facebookfacebook.com/profile.php
• LinkedInlinkedin.com/company/bpi-labs

Compliance2 records

Revenue estimate

Valuation estimate

Number of profiles

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about BPI Labs